DotBio is focused on the development of novel immuno-oncology drugs based on humanized domain antibodies, its proprietary DotBody technology. DotBodies are domain therapeutic antibodies which are multi-specific, humanized and highly-stable. The company was founded by Professor Pär Nordlund and Dr. Ignacio Asial, who designed and conceptualized the DotBody technology based on their expertise in protein and antibody engineering at Singapore’s Nanyang Technological University. For more information visit www.dotbiopharma.com
| Website | http://www.dotbiopharma.com |
| Employees | 24 (12 on RocketReach) |
| Founded | 2018 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+10 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Clinical Development, Therapeutic Antibodies, Preclinical Development, Molecular Biology, Novel Therapeutics, Biotechnology, Protein Engineering, Drug Development, Pharmaceutical, Drug Discovery, Cancer Treatment, Oncology, Immunotherapy, Biopharma, Therapeutics, Medicine |
| Competitors | Roche, Amgen, Gilead Sciences, AbbVie, Genentech, Sanofi, Regeneron, Moderna Therapeutics, Sobi - Swedish Orphan Biovitrum AB (publ), Lilly India +41 more (view full list) |
Looking for a particular DotBio employee's phone or email?
DotBio Questions
Ignacio Asial is the Founder, CEO of DotBio.
12 people are employed at DotBio.
Top DotBio Employees
-
Ignacio Asial
Founder, CEO at DotBio
Singapore4 -
1
-
5+4
-
21
-
Elena Okina
Project Manager at DotBio
Singapore -
Dylan Seah
Intern at DotBio
Singapore -
Ong Qi
Research Associate at DotBio
Singapore1 -
Shuang Ng
Research Associate at DotBio
Singapore1 -
Shimin Jiang
Senior Scientist at DotBio
Singapore1
Related Companies
